Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2024-04-11 Notice of Dividend Amou…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ASTRAZENECA INCREASES 2024 DIVIDEND BY 7%
Notice of Dividend Amount Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, indicating it is a report of a foreign issuer. The content focuses on the announcement of a 7% increase in the 2024 dividend, detailing the dividend amount and payment timetable. The document length is 3501 characters, which is relatively short and primarily serves as an announcement rather than a detailed financial report. There are no financial statements or comprehensive analysis present. The key content is the dividend increase announcement, which fits the category of Notice of Dividend Amount filings. Therefore, the appropriate classification is DIV (Notice of Dividend Amount).
2024-04-11 English
AstraZeneca increases 2024 dividend by 7%
Notice of Dividend Amount Classification · 99% confidence The document is a short announcement released via RNS (Regulatory News Service) on April 11, 2024. The primary content explicitly states: 'AstraZeneca increases 2024 dividend by 7%' and details the new annualized dividend amount ($3.10 per share). This directly corresponds to the definition of a Notice of Dividend Amount (DIV). Although it is distributed via RNS, the specific nature of the announcement (dividend increase) makes DIV the most accurate classification over the general RNS fallback.
2024-04-11 English
ENHERTU APPROVED IN US FOR HER2+ SOLID TUMOURS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the FDA approval of Enhertu for HER2+ solid tumors, including clinical trial data, regulatory designations, and collaboration details. Form 6-K filings are typically used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. This document is not an annual report, earnings release, or any other specific report type but rather a regulatory announcement of material information. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a report publication announcement but a substantive regulatory filing.
2024-04-08 English
Enhertu approved in US for HER2+ solid tumours
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and the date '08 April 2024', indicating it is a regulatory announcement. The content details the US FDA approval of the drug Enhertu for a specific cancer indication, citing clinical trial results and quoting company executives. This type of announcement, which is a formal communication to the market about a significant event (like a drug approval), is characteristic of a Regulatory News Service (RNS) filing. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV), the most appropriate general category for a market-sensitive regulatory update that isn't covered by a more specific code is RNS.
2024-04-08 English
IMFINZI IMPROVED OS & PFS IN LIMITED-STAGE SCLC
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about clinical trial results (ADRIATIC Phase III trial) for the drug Imfinzi in limited-stage small cell lung cancer, including survival benefits and safety profile. The document is a regulatory filing to disclose material information to the SEC and investors, but it is not an annual or interim financial report, earnings release, or any other specific financial report type. It is a standalone regulatory announcement of clinical trial results and related corporate information. The document length is 12,890 characters, indicating it is a full report rather than a brief announcement. However, it does not contain financial statements or management discussion of financial results. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-05 English
Imfinzi improved OS & PFS in limited-stage SCLC
Earnings Release Classification · 99% confidence The document begins with 'National Storage Mechanism' and prominently features 'RNS Number : 4110J' and the date '05 April 2024'. The content is a press release announcing positive Phase III trial results for the drug Imfinzi in small cell lung cancer. This type of announcement, which disseminates material, time-sensitive information via an official news service (RNS, regulated by the FCA), is typically classified as a general Regulatory Filing or an Earnings Release if it contained summary financials. Since this is a clinical trial update and not a standard periodic financial report (like 10-K or IR), and it is clearly distributed through the RNS system, the most appropriate classification is the general regulatory announcement category, RNS, as it is a primary information provider announcement. Q2 2024
2024-04-05 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.